Novo Nordisk's next-gen obesity drug Cagrisema
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...
Central obesity measures of waist circumference and waist-to-hip ratio appear to be more accurate and consistent indicators of colorectal cancer incidence compared with BMI, according to a study ...
In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...
Recently, an international commission proposed a revised definition of obesity that focuses on how excess body fat affects the body, and factors in waist circumference, rather than simply ...
GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...
The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
Experts from AIIMS Delhi emphasised obesity’s harmful health effects and the need for preventive actions, supporting Prime ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback